⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11859333 | 0.86 | ALDH1A1 (0.32) | — | |
| SCHEMBL17252177 | 0.86 | FFAR3 (0.32) | — | |
| SCHEMBL769660 | 0.83 | — | — | |
| SCHEMBL7407268 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL4440847 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL3719108 | 0.81 | — | — | |
| SCHEMBL14119567 | 0.81 | — | — | |
| SCHEMBL15116609 | 0.81 | — | — | |
| SCHEMBL2602334 | 0.81 | — | — | |
| SCHEMBL14128893 | 0.81 | NPSR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991004754-A2 | ILLUDIN ANALOGS AS ANTI-TUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-04-18 | — | — | WO | claimed |
| WO-2017205191-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2017036405-A1 | COMPOUND HAVING PROTEIN TYROSINE PHOSPHATASE SHP-1 AGONIST ACTIVITY | 陈昆锋 | 2017-03-09 | — | — | WO | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| EP-0683762-B1 | ACYLFULVENE ANALOGUES AS ANTITUMOR AGENTS | UNIV CALIFORNIA (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5563176-A | Illudin analogs useful as antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0565519-B1 | ILLUDIN ANALOGS AS ANTI-TUMOR AGENTS | UNIV CALIFORNIA (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5523490-A | ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-06-04 | — | — | US | disclosed |
| CN-1119854-A | Acylfulvene analogues as antitumor agents | UNIV CALIFORNIA (US) | 1996-04-03 | — | — | CN | disclosed |
| EP-0683762-A1 | ACYLFULVENE ANALOGUES AS ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5439942-A | Administering an anticarcinogenic agents, adjuvants with surgical or radiation therapy; cytolysis, side effect reduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-08 | — | — | US | disclosed |
| US-5439936-A | Administering an acylfulvene anticarcinogenic agents, adjuvants with surgical or radiation therapy; side effect reduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1994018151-A1 | ACYLFULVENE ANALOGUES AS ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1991004754-A2 | ILLUDIN ANALOGS AS ANTI-TUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-04-18 | — | — | WO | disclosed |